Innovative Technology Leuko has developed a groundbreaking non-invasive white blood cell monitoring device based on MIT research, offering a portable, at-home testing solution that eliminates the need for blood draws. This innovative approach presents significant opportunities to partner with healthcare providers and clinics looking to enhance patient comfort and streamline testing procedures.

Strong Funding Support With recent grants totaling over 4.5 million dollars from the NIH and a Series A funding of 5 million dollars, Leuko demonstrates strong investor confidence and financial stability. This funding can be leveraged to accelerate commercialization efforts and expand sales channels into hospitals, cancer centers, and diagnostic labs.

Strategic Collaborations Leuko has established partnerships with leading cancer treatment centers such as MD Anderson and Boston Medical Center, validating its technology in high-profile clinical settings. These collaborations open doors to placement opportunities, pilot programs, and revenue streams within prestigious healthcare institutions.

Market Expansion Potential Targeting attention on cancer management, chemotherapy monitoring, and infectious disease detection, Leuko's device addresses a broad and growing medical market. Engaging with pharmaceutical companies and healthcare providers involved in oncology and infectious diseases can create new sales avenues.

Growth & Scale With a small but skilled team of up to 50 employees and a revenue range of 1 to 10 million dollars, Leuko is poised for growth. Business development efforts focused on strategic partnerships, hospital integrations, and insurance reimbursement pathways can facilitate rapid expansion into the medical equipment market.